Methylglyoxal-derived advanced glycation endproducts in multiple sclerosis

Wetzels, Suzan; Wouters, Kristiaan; Schalkwijk, Casper G.; Vanmierlo, Tim & Hendriks, Jerome J. A. (2017) Methylglyoxal-derived advanced glycation endproducts in multiple sclerosis. In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 18(2), p. 1-15 (Art N° 421).

DOI: 10.3390/ijms18020421
Handle: http://hdl.handle.net/1942/23723
Review

Methylglyoxal-derived advanced glycation endproducts in multiple sclerosis

Suzan Wetzels 1,2, Kristiaan Wouters2*, Casper Schalkwijk2, Tim Vanmierlo1# and Jerome JA Hendriks1

1 Department of Immunology and Biochemistry, BIOMED, Hasselt University, Martelarenlaan 42 3500 Hasselt, Belgium; suzan.wetzels@uhasselt.be, tim.vanmierlo@uhasselt.be, jerome.hendriks@uhasselt.be
2 Department of Internal Medicine, Maastricht University, 6229 Maastricht, the Netherlands + CARIM; suzan.wetzels@uhasselt.be, kristiaan.wouters@maastrichtuniversity.nl, c.schalkwijk@maastrichtuniversity.nl
* Correspondence: jerome.hendriks@uhasselt.be; Tel.: +32-11-26-9207
# Authors contributed equally

Abstract: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS). Activation of inflammatory cells is crucial for the development of MS and is shown to induce intracellular glycolytic metabolism in pro-inflammatory microglia and macrophages as well as CNS-resident astrocytes. Advanced glycation endproducts (AGEs) are stable endproducts formed by a reaction of the dicarbonyl methylglyoxal (MGO) and glyoxal (GO) with amino acids in proteins during glycosylation. This suggests that, in MS, MGO-derived AGEs are formed in glycolysis-driven cells. MGO and MGO-derived AGEs can further activate inflammatory cells by binding to the receptor for advanced glycation endproducts (RAGE). Recent studies revealed that AGEs are increased in the plasma and brain of MS patients. Therefore, AGEs might contribute to inflammatory status in MS. Moreover, the main detoxification system of dicarbonyl compounds, the glyoxalase system, seems to be affected in MS patients which may contribute to high MGO-derived AGE levels. Altogether, evidence is emerging for a contributing role of AGEs in the pathology of MS. In this review, we provide an overview of current knowledge on the involvement of AGEs in MS.

Keywords: multiple sclerosis; methylglyoxal; advanced glycation endproducts; glyoxalase system; receptor for advanced glycation endproducts

1. Introduction

Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system (CNS) [1]. MS mainly manifests between the ages 20 – 40, affecting women twice as often as men [2]. The typical disease course, occurring in about 85% of MS patients, is relapsing-remitting (RR)-MS, in which there are episodes of acute neurological deficits (relapses) that result in disability with full recovery between relapses [3]. Sixty-five percent of the RR-MS patients enter the secondary progressive stage of MS (SP-MS) within 5 – 15 years after the initial diagnosis [4]. The SP-MS phase is characterized by incomplete recovery between relapses and progression of the disease. Fifteen percent of MS patients show a progressive course from onset of the disease without relapses and remission. These patients are categorized as primary-progressive MS (PP-MS) patients. MS patients show a wide variety of symptoms, such as visual disturbance, paresthesia, ataxia, and muscle weakness which originate from the damaged areas in the CNS [5].

MS is a complex disease. It is generally assumed that MS is triggered by environmental factors in genetically susceptible hosts. Family studies revealed the genetic component in MS and...
demonstrated a 20-33% family recurrence rate and an 10-12 fold risk increase in first degree relatives [6]. Several genes are associated with MS susceptibility, especially genes encoding for the major histocompatibility complex (HLA DRB1*1501, HLA DQA1*0102, HLA DQB1*0602), which are responsible for 50% of the genetic risk for MS [7]. Genome-wide association studies (GWAS) linked other immune-related genes to MS risk including genes encoding the interleukin (IL)-17 receptor and IL-2 receptor, cytokines such as IL-12A and IL-12β, and genes associated with co-stimulatory molecules including CD80, CD86, and CD37 [6]. In addition to genetic factors, there are also environmental factors that can contribute to the development of MS such as active smoking [8], reduced levels of vitamin D [9], and infection with the Epstein-Barr virus [10] are confirmed risk factors for MS [11]. Reduced levels of vitamin D are linked with the geographic spread of MS, as these levels positively correlate with increasing latitude [12] due to reduced exposure to sunlight which is necessary for vitamin D production in the skin.

MS is an autoimmune disease of the CNS. The autoimmune response, which mainly involves autoreactive T-lymphocytes, macrophages and CNS-resident microglia, is directed against CNS antigens [13]. Macrophages and microglia contribute to neuroinflammation and neurodegeneration by the secretion of pro-inflammatory mediators such as cytokines and chemokines, the degradation and phagocytosis of myelin, and presentation of myelin antigens to autoreactive T-lymphocytes [13]. The interplay between the innate (e.g. macrophages and microglia) and the adaptive immune system at target locations is essential, as infiltrating T-lymphocytes require antigen presentation in order to be re-stimulated [14]. In addition to the cells of the immune system, astrocytes can also contribute to neuroinflammation since they exhibit functions that are similar to immune cells such as production of pro-inflammatory cytokines and chemokines [15].

It is clear that during MS, the CNS myelin is under attack by immune cells. There are two hypotheses for the role of immune cells in the development of lesions. First, a major hypothesis in MS pathology is that immune activation for a specific CNS antigen occurs in the periphery and is then relocated to the CNS, the so-called “outside-in hypothesis” [16,17]. The activation of immune cells, mostly CD4+ T-lymphocytes, is thought be a result of molecular mimicry in which cells are primed with a foreign antigen that resembles structures of autoantigens. The second, opposing, hypothesis states that an initiating event within the CNS, a primary infection or neuronal disturbances, causes activation of resident microglia, and is called the “inside-out hypothesis” [16].

This immune reaction in the CNS leads to resident recruitment of innate and adaptive immune cells from the periphery which will aggravate CNS inflammation. However, to this date the exact cause of MS remains unknown.

2. Advanced Glycation Endproducts

AGEs are increased in inflammatory diseases such as diabetes [18,19], atherosclerosis [19,20], obesity [21], and nonalcoholic steatohepatitis [22], but also neuro-inflammatory diseases such as Alzheimer’s disease [23] and Parkinson’s disease [24]. Gaens et al. revealed that the AGE Nε-(carboxymethyl)lysine (CML) is significantly increased in liver [22] and visceral adipose tissue [21] of obese patients compared to controls, which was related to an increase in pro-inflammatory makers and thus inflammation. In Alzheimer’s disease, β-amyloid peptides depositions and neurofibrillary tangles are affected by glycation [25,26]. Moreover, Dalfó et al. have shown that glycation is present in the cerebral cortex, amygdala, and substantia nigra of healthy subjects and that these are increased in Parkinson’s disease patients [24]. Also, AGEs are increased in the plasma and brain of MS patients [27,28]. Accumulation of AGEs in the plasma and CNS of MS patients may contribute to neuroinflammation and the progression of MS.

2.1 Formation of AGEs

AGEs are stable endproducts of a non-enzymatic glycation reaction. The formation of AGEs (the Maillard-reaction) starts with the reaction of sugar aldehydes with the N-terminus of free-amino groups of proteins to form a so-called Schiff base [29]. Rearrangements of the instable Schiff base
leads to the formation of Amadori products. A small subset of Amadori products will undergo
further irreversible reactions leading to the formation of AGEs [29,30]. Frequently formed AGEs are
N\(^{\text{\-}}\)-(carboxymethyl)lysine (CML), N\(^{\text{\-}}\)-(carboxyethyl)lysine (CEL), and pentosidine. The formation of
AGEs via the Maillard-reaction is a slow process taking weeks. In addition to the slow reaction it is
becoming clear that the majority of AGEs in vivo are mainly formed in a fast reaction of dicarbonyl
compounds such as methylglyoxal (MGO) and glyoxal (GO) with proteins [29].

2.2 Formation and Detoxification of Methylglyoxal

MGO is produced as a byproduct of glycolysis via the fragmentation of triosephosphates
glyceraldehyde-3-phosphate (GAP) and dihydroxyacetone phosphate (DHAP) as shown in figure 1
[31,32]. In addition, glyoxal can be created directly from glucose via a retro-aldol condensation
reaction and indirectly via GAP [33]. Moreover, reactive dicarbonyl compounds can also be formed
as a result of lipid peroxidation creating so called advanced lipoxidation endproducts (ALEs). Lipid
peroxidation of polyunsaturated fatty acids occurs under circumstances with increased oxidative
stress and high amounts of reactive oxygen species (ROS). This will lead to the formation of lipid
peroxides. Lipid peroxides undergo fragmentation to produce reactive carbonyl compounds such as
malondialdehyde (MDA) and 4-hydroxynonenal (HNE), but also the dicarbonyl compounds MGO,
and GO (Figure 1) [34].

![Diagram of glycolysis and formation of AGEs/ALEs](image-url)

**Figure 1.** Formation of reactive dicarbonyl compounds and AGEs/ALEs via glucose and lipid
intermediates. During glycolysis, glucose is converted into pyruvate and subsequently into lactate.
Fragmentation of glyceraldehyde-3P (GAP) and DHAP leads to the formation of methylglyoxal and
glyoxal. In addition to glycolysis, lipid peroxidation of polyunsaturated fatty acids leads to the
formation of lipid peroxides that can undergo fragmentation resulting in the formation of
malondialdehyde, 4-hydroxynonenal, methylglyoxal and glyoxal. Moreover, glyoxal can be created
directly from glucose via retro-aldol condensation reaction. Incubation of these highly reactive
compounds with proteins, lipids, and nucleic acids leads to the fast formation of AGEs and ALEs.
Methylglyoxal and glyoxal are detoxified via the glyoxalase system. First, methylglyoxal and glyoxal
are converted to S-Lactoylglutathione by Glo1 which uses glutathione as a cofactor. Subsequently,
S-Lactoylglutathione is metabolized to D-lactate by Glo-2. Glutathione gets recycled during this last step in the process.

Since there is a great variety in free-amino groups in proteins, lipids, and nucleic acids, AGEs and ALEs represent a diverse and very large group of modifications. Interaction of MGO with arginine leads to the formation of specific AGEs methylglyoxal-derived hydromidazolone 1 (MG-H1) and tetrahydropyrimidine (THP) [35]. In addition, MGO and GO can react with lysine to form CEL and CML, respectively. Since MGO and GO are formed during glycolysis and during lipid peroxidation, CML and CEL can be regarded as both AGEs and ALEs [29].

Intracellular accumulation of reactive carbonyls MDA and HNE and dicarbonyl compounds MGO and GO, are highly toxic because these compounds are potent glycating agents [31]. To reduce the toxic effects of reactive (di)carbonyl compounds and the formation of AGEs/ALEs, the body has several defense systems such as glyoxalase, aldose reductase, aldehyde dehydrogenase, and carbonyl reductase pathways [31,33]. The glyoxalase system is the main defense system to reduce the toxicity of reactive dicarbonyl compounds. MGO, and to a lesser extent GO, is detoxified by the glyoxalase system, a ubiquitous enzymatic pathway present in cytoplasm [32]. There are two enzymes responsible for the detoxification: glyoxalase-1 (Glo-1) and glyoxalase-2 (Glo-2). First MGO is converted to S-Lactoylglutathione by Glo1 which uses glutathione (GSH) as a cofactor (Figure 1). Subsequent, S-Lactoylglutathione is metabolized to D-lactate by Glo-2. GSH gets recycled during this last step in the process, making it available for new detoxification of MGO. The conversion of MGO by Glo1 is important because this is the rate-limiting step and S-Lactoylglutathione is not as toxic to cells as MGO.

2.3 Biological effects of Methylglyoxal and Advanced Glycation Endproducts

MGO can have several direct effects. MGO increases oxidative stress by inducing superoxide (O$_2^-$), hydrogen peroxide (H$_2$O$_2$), and peroxynitrite (ONOO-) but also by decreasing antioxidants and their mechanisms [36]. Moreover, cultured neuronal cells upregulate IL-1β expression and secretion after MGO stimulation [37], thereby contributing to inflammation. MGO is also able to induce apoptosis by increasing the Bax/Bcl-2 ratio and activation of caspase-9 and caspase-3, promoting the mitochondrial apoptosis pathway [38]. In addition to these direct effects, MGO is a potent glycating agent resulting in the formation of AGEs which have biological effects by three general mechanisms. First, protein function can be altered by intracellular glycation of proteins resulting in distorted cell function [39]. Second is the modification of extracellular matrix proteins by AGEs leading to altered interactions between the cells and proteins [40,41]. The third mechanism is the binding of AGEs to a variety of cell surface receptors leading to the activation of downstream signaling pathways. The most described receptor is the multi-ligand receptor for advanced glycation end-products (RAGE). This receptor not only binds AGEs but also amyloid proteins, high-mobility group B (HMGB), Mac-1 and S100 proteins [42,43] and is thought to be expressed on a variety of cell types involved in MS such as, monocytes/macrophages, T-lymphocytes, astrocytes, and endothelial cells. The binding of ligand to RAGE leads to increased intracellular oxidative stress and activation of NF-κB, which increases the production of pro-inflammatory cytokines like IL-1α, IL-6 and TNFα [30,40]. However, there are more receptors known that bind AGEs such as AGER1 [30,42] which is also expressed on monocytes/macrophages, T-lymphocytes, endothelial cells, and smooth muscle cells. AGER1 is a type I transmembrane protein that is supposed to facilitate AGE turnover by mediating uptake, degradation, and removal of AGEs [41]. Moreover, AGER1 activation reduces the effects of RAGE signaling by deacetylation of NF-κB via sirtuin-1 [41]. Therefore, AGER1 contributes to an anti-inflammatory status as its signaling pathway leads to a decrease in oxidative stress and pro-inflammatory cytokines.

3. Advanced Glycation Endproducts in Multiple Sclerosis
There are several studies that have shown differences in AGE levels in MS patients compared to controls. Moreover, there is evidence that AGEs contribute to the disease progression in MS. In the next part, we will summarize the literature describing AGE levels, effects of AGEs, the glyoxalase system, the role of glycolysis, lipid peroxidation, and the receptor for advanced glycation end-products in MS.

### 3.1 Alterations in Advanced Glycation Endproduct levels in Multiple Sclerosis

Previous research demonstrated that AGEs are increased in the plasma and brain of MS patients [27,28]. Sternberg et al. investigated the diagnostic potential of plasma AGEs, specifically CML and CEL, in MS patients and healthy controls. The results showed that CEL plasma levels, but not CML levels, are higher in MS patients compared to healthy controls [27]. Disease modifying treatments (DMTs) reduced CEL plasma concentrations. Furthermore, the presence of CML and RAGE was determined in paraffin-embedded brain sections of four relatively young MS patients [28]. It was found that CML and RAGE are expressed in astrocytes and macrophages within and in close proximity of MS lesions. These studies have shown that AGEs are present in the brain and plasma of MS patients, however, it would be interesting to quantify the AGEs levels in the brain of MS patients and compare these levels to controls to determine whether the increase of AGEs seen in the plasma of MS patients also reflects the AGE levels in the CNS as this is the site where AGEs can activate their target cells.

### 3.2 The effects of Advanced Glycation Endproducts on key cells in MS development

Methylglyoxal is a potent glycating agent, leading to increased levels of MGO-derived AGEs which can exert their effects via their receptor RAGE. Key cells in MS development such as microglia, astrocytes, and endothelial cells (in the BBB), express RAGE making them targets for AGEs. It can be hypothesized that MGO-derived AGEs act as accelerators of MS lesion pathology and function as a detrimental positive feedback loop, as illustrated in Figure 2. It has been reported that activation of microglia by AGEs leads to an increased expression and secretion of pro-inflammatory cytokines, such as TNFα, IL-1β, and IL-6 [44-46]. Moreover, stimulation with AGEs leads to increased levels of RAGE [46,47], creating a positive feedback loop that promotes inflammation. In addition to microglia, astrocytes are abundantly present in the CNS and also express RAGE making them susceptible for AGE-RAGE activation. Indeed, it is reported that stimulation of astrocytes with glucose-modified bovine serum albumin, which can be regarded as AGEs, leads to increased TNFα and IL-6 secretion [48]. Furthermore, a glucose rich environment, which is present in the CNS of MS patients, induces a pro-inflammatory phenotype in astrocytes which contributes neuroinflammation.
Inflammation

**Figure 2.** Schematic overview of the effects of MGO on key cells in MS development. The inflammatory environment in the CNS during MS leads to an increase in glycolysis in astrocytes and microglia. This induces the production of MGO and subsequently AGEs. AGEs activate RAGE, which is present on astrocytes, microglia, and endothelial cells, leading to increased oxidative stress, production of pro-inflammatory cytokines, and increased RAGE expression. Moreover, the BBB is affected by AGEs leading to loss of tight-junction proteins and thereby increasing permeability. Several positive feedback loops (dashed lines) are possible to further stimulate the inflammatory environment and moreover, increasing the AGE levels in the CNS. The upregulation of RAGE upon its activation leads to increased pathway activation and thus oxidative stress and pro-inflammatory cytokines. Moreover, the production of pro-inflammatory cytokines contributes to the inflammatory status of the CNS. In addition, oxidative stress depletes GSH leading to decreased Glo1 activity, and stimulates lipid peroxidation, all contributing to the production of MGO among others.

The blood-brain barrier (BBB) is required to maintain homeostasis within the CNS and block the entry of toxic stimuli, infectious agents, and peripheral immune cells. The BBB consist of endothelial cells that are attached to each other by tight junctions. These tight junctions, comprised of different tight junction proteins such as occludins and claudins, restrict the passive influx of molecules and cells into the CNS [49]. Moreover, besides endothelial cells, astrocytes and pericytes are present supporting the BBB. Endothelial cells of the BBB are affected when stimulated with AGEs leading to loss of tight junction protein expression and thus increasing the permeability of the BBB [50,51]. In addition, endothelial cells secrete pro-inflammatory cytokines that contribute to inflammation. Glycation of the underlying matrix proteins was shown to lead to increased BBB permeability [50]. AGE-activated astrocytes increase the production of vascular endothelial growth factor and decrease the production of glial cell line-derived neurotrophic factor also leading to an
increase of BBB permeability [52]. Taken all these results together, we can hypothesize that AGE act
as accelerators of MS lesion pathology by inducing a pro-inflammatory phenotype in microglia and
astrocytes. This also leads to increased RAGE expression, which can act as a positive feedback loop
by inducing more pro-inflammatory mediators. In addition, AGEs disrupt BBB function which leads
to increased infiltration of peripheral immune cells into the CNS, contributing to neuroinflammation
and neurodegeneration.

3.3 The Glyoxalase System in Multiple Sclerosis

The major precursor in the formation of AGEs, MGO, and to a lesser extent GO, can be
detoxified by the glyoxalase system. As mentioned before, this system uses GSH as a cofactor, which
is reused in the glyoxalase system as D-lactate is formed. In the CNS, the level of GSH is maintained
by active intracellular GSH synthesis originating from astrocytes, but also from neurons [53]. In
addition to the de novo synthesis, GSH can be recycled by glutathione reductase which converts the
oxidized form of glutathione (GSSH) to the reduced form (GSH). In 2002, Calabrese et al. determined
the amount of GSH in cerebrospinal fluid (CSF) samples of MS with the NADPH-dependent GSSG
reductase method, revealing significantly decreased GSH in the CSF of MS patients [54]. Moreover,
Choi et al. developed a method to non-invasively measure GSH in vivo using MRI and found that
GSH in the fronto-parietal area in the brain was significantly decreased in SPMS patients compared
to controls [55,56]. The decrease in GSH concentration in MS patients may limit the detoxification of
MGO by glyoxalase system and this leads to accumulation of MGO in the cells, ultimately leading to
an increase in MGO-derived AGEs. In addition to GSH availability, Sidoti et al. determined the
frequency of the A111E polymorphism present in the Glo-1 gene as this particular polymorphism is
known to have a decreased detoxification capacity [57]. The frequency of the EE genotype was
significantly increased in RR-MS patients compared to controls (59.8% vs. 49.3%, p<0.0001) [58]
suggesting that decreased Glo-1 activity can contribute to increased MGO-derived AGE-levels in MS
patients compared to controls.

3.4 Increased Glycolysis as an underlying Mechanism for the formation of Methylglyoxal-derived Advanced
Glycation Endproducts in Multiple sclerosis

The formation of AGEs via reactive dicarbonyl compounds mainly occurs in highly metabolic
active cells which rely on glycolysis such as macrophages [59], microglia [60] and astrocytes [61-63].
Already in 1962, Karnovsky reported that phagocytosis leads to increased glycolysis in macrophages
[64]. This implicates that in MS glycolysis is increased in phagocytes after uptake of myelin.
Supporting this, Bogie et al. revealed using micro-array analysis of myelin treated macrophages that
genes involved in glycolysis are induced [65] which likely results in the formation of AGEs in myelin
containing macrophages.

Glucose is the main energy source of the brain where the energy requirements are high [66].
Nijland et al. investigated the distribution of specific glucose transporters in brain tissue of MS
patients and non-neurological controls and found that glucose transporter 1 (GLUT1) and 4 (GLUT4)
are increased in MS lesions [67]. GLUT1 is expressed in the brain microvasculature which ensures
transport of glucose over the BBB and uptake of glucose by astrocytes [68]. GLUT4 is expressed on
astrocytes and endothelial cells. It is known that demyelinated axons require more energy to
maintain proper conduction of signals [69]. Therefore, an upregulation of nutrient transporters
within MS lesions and increased glycolysis is necessary. Indeed, previous studies have revealed that
MS patients have an increased glucose and lactate metabolism within lesions in the CNS which was
observed with positron emission tomography and magnetic resonance spectroscopy [70,71]. The
energy needed for signaling processes such as postsynaptic and action potentials, comes mainly
from astrocytes, featured by a high glycolytic rate [61-63]. In addition to astrocytes, oligodendrocytes
also appear to be glycolytic since the glycolytic activity is higher in white matter which consists of
high numbers of oligodendrocytes compared to grey matter [72]. Funfschilling et al. proposed a
hypothetical model in which glucose is used for ATP generation and serves the synthesis of myelin
lipids at the onset of myelination [73]. Moreover, it is also suggested that in post-myelinated oligodendrocytes glycosylation is used to maintain survival. These data indicate that in MS not only the astrocytes but also oligodendrocytes are a potential source of glycosylation-derived reactive dicarbonyl compounds and thus of AGEs.

3.5 Increased Lipid Peroxidation as an underlying Mechanism for the formation of Methylglyoxal-derived Advanced Glycation Endproducts in Multiple Sclerosis

In addition to glycosylation-derived formation of AGEs, AGEs are also formed during lipid peroxidation via the formation of reactive carbonyls MDA and HNE and dicarbonyl compounds, such as MGO and GO. The formation of lipid-derived AGEs is initiated by reactive oxygen species (ROS) (Figure 1) [34]. ROS are highly reactive small molecules that have an unpaired electron and have the ability to give rise to new free radicals [74]. ROS production can be rapidly increased due to oxidative phosphorylation in mitochondria, phagocytosis, and enzymatic reactions which catalyze oxidases [75]. Under physiological conditions, concentrations of ROS remain low as a result of anti-oxidative mechanisms which include enzymatic reactions (superoxide dismutase and catalase) and non-enzymatic molecules (vitamin C, vitamin E, GSH). However, the CNS is sensitive to oxidative stress and the production of ROS due to the high rate of oxygen utilization and a relatively poor anti-oxidant defense system [76]. In addition, immune cells are a great source of ROS. During MS, activated microglia and infiltrated monocyte-derived macrophages accumulate in the CNS. Both microglia and macrophages produce large quantities of ROS [77]. A recent study from Guan et al. showed that MS patients have increased levels of the lipid peroxidation marker 8-iso-PGF2α in their urine compared to healthy controls, indicating that lipid peroxidation is increased [78]. Moreover, the levels of urinary 8-iso-PGF2α corresponded with MS disease severity. Since the CNS is rich in polyunsaturated fatty acids, an increased amount of lipid peroxides can be formed due to lipid peroxidation. Van Horssen et al. compared the oxidative damage in MS lesions to normal appearing white matter (NAWM) and healthy controls [79]. Data from this study revealed that oxidative damage to proteins, nucleotides as well as lipids is increased in MS lesions compared to NAWM and controls. Furthermore, this oxidative damage was mostly found in hypertrophic astrocytes and phagocytic macrophages in active demyelinated lesions [79]. Moreover, Wang et al. revealed that MDA, a reactive carbonyl compound which is able to induce ALEs, is elevated in RR-MS patients [80]. The results from the above studies show that oxidative stress and lipid peroxidation are increased in MS patients. This may lead to an increased MGO, and subsequently AGE production in MS patients.

3.6 Receptors for Advanced Glycation Endproducts in Multiple Sclerosis

RAGE is expressed on various cell types that are involved in MS. Andersson et al. determined that RAGE was upregulated in active MS lesions and in CNS lesions in experimental autoimmune encephalomyelitis (EAE), an animal model of MS [81]. In 2003, Yan et al. examined the role of RAGE during EAE development and in MS [82]. It was shown that RAGE immunoreactivity is increased in brain samples from MS patients, especially in mononuclear phagocytes and CD4+ T cells. This was confirmed in the spinal cord tissue of EAE mice. There is also experimental evidence that RAGE contributes to the disease progression of MS. Treatment of EAE mice with sRAGE, the cleaved variant of RAGE which prevents activation of membrane-bound RAGE [83], or specific RAGE blocking antibodies protects them partially from developing EAE, suggesting that the activation of RAGE by ligands is necessary for the development of EAE. In contrast, Liliensiek et al. found that full body RAGE deficiency (RAGE-/-) did not affect EAE development [84]. However, cell specific overexpression of RAGE on hematopoietic and endothelial cells led to a significant increase in EAE severity compared to wild type controls. This suggests that RAGE expression on immune and endothelial cells is involved in the perpetuation but not in the initiation of neuroinflammation [84]. These data, showing no protective effect of full body RAGE deficiency during EAE development, are in contrast with the data of Yan et al., who revealed that treatment with sRAGE partially protects
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations

AGER1 Advanced Glycation Endproduct Receptor 1
AGEs Advanced Glycation Endproducts
ALEs Advanced Lipoxidation Endproducts
BBB blood-brain barrier
CD Cluster of Differentiation
CEL ω-(carboxyethyl)lysine
CML ω-(carboxymethyl)lysine
CNS Central Nervous System
CSF Cerebrospinal Fluid
DHAP Dihydroxyacetone Phosphate
DMTs Disease Modifying Treatments
EAE Experimental Autoimmune Encephalomyelitis
EDSS Expended Disability Status Score
GAP Glyceraldehyde-3-phosphate
Glo-1 Glyoxalase-1
Glo-2 Glyoxalase-2
GLUT Glucose Transporter
GO Glyoxal
GSH Glutathione
GWAS Genome-wide Association Studies
HLA Human Leukocyte Antigen
HMGB High-Mobility Group B
HNE 4-Hydroxynonenal
IL Interleukin
MDA Malondialdehyde
MG-H1 Methylglyoxal-derived Hydroimidazolone 1
MGO Methylglyoxal
MS Multiple Sclerosis
NADPH Nicotinamide Adenine Dinucleotide Phosphate
NAWM Normal Appearing White Matter
NF-κB Nuclear Factor-κB
PBMCs Peripheral Blood Mononuclear Cells
PP-MS Primary Progressive Multiple Sclerosis
RAGE Receptor for Advanced Glycation Endproducts
ROS Reactive Oxygen Species
RR-MS Relapsing Remitting Multiple Sclerosis
SP-MS Secondary Progressive Multiple Sclerosis
sRAGE Soluble Receptor of Advanced Glycation Endproducts
THP Tetrahydropyrimidine
TNFα Tumor Necrosis Factor alpha

References

1. Compston, A.; Coles, A. Multiple sclerosis. *Lancet* 2008, 372, 1502-1517.
2. Bar-Or, A.; Oliveira, E.M.; Anderson, D.E.; Hafler, D.A. Molecular pathogenesis of multiple sclerosis. *Journal of neuroimmunology* 1999, 100, 252-259.
3. Ellwardt, E.; Zipp, F. Molecular mechanisms linking neuroinflammation and neurodegeneration in ms. *Exp Neurol* 2014.
4. Scalfari, A.; Neuhaus, A.; Daumer, M.; Muraro, P.A.; Ebers, G.C. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. *Journal of neurology, neurosurgery, and psychiatry* 2014, 85, 67-75.
5. Duffy, S.S.; Lees, J.G.; Moalem-Taylor, G. The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis. *Multiple sclerosis international* 2014, 2014, 285245.
6. Hoglund, R.A.; Maghazachi, A.A. Multiple sclerosis and the role of immune cells. *World journal of experimental medicine* 2014, 4, 27-37.

7. Ortiz, G.G.; Pacheco-Moises, F.P.; Macias-Islas, M.A.; Flores-Alvarado, L.J.; Mireles-Ramirez, M.A.; Gonzalez-Renovato, E.D.; Hernandez-Navarro, V.E.; Sanchez-Lopez, A.L.; Alatorre-Jimenez, M.A. Role of the blood-brain barrier in multiple sclerosis. *Archives of medical research* 2014, 45, 687-697.

8. Hedstrom, A.K.; Baarnhielm, M.; Olsson, T.; Alfredsson, L. Tobacco smoking, but not swedish snuff use, increases the risk of multiple sclerosis. *Neurology* 2009, 73, 696-701.

9. Munger, K.L.; Zhang, S.M.; O’Reilly, E.; Hernan, M.A.; Olek, M.J.; Willett, W.C.; Ascherio, A. Vitamin D intake and incidence of multiple sclerosis. *Neurology* 2004, 62, 60-65.

10. Levin, L.I.; Munger, K.L.; O’Reilly, E.J.; Falk, K.I.; Ascherio, A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. *Annals of neurology* 2010, 67, 824-830.

11. Mallucci, G.; Peruzzi-TJametti, L.; Bernstock, J.D.; Pluchino, S. The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. *Progress in neurobiology* 2015, 127-128, 1-22.

12. Simpson, S., Jr.; Blizard, L.; Otahal, P.; Van der Mei, I.; Taylor, B. Latitude is significantly associated with the prevalence of multiple sclerosis: A meta-analysis. *Journal of neurology, neurosurgery, and psychiatry* 2011, 82, 1132-1141.

13. Boggie, J.F.; Stinissen, P.; Hendriks, J.J. Macrophage subsets and microglia in multiple sclerosis. *Acta Neuropathol* 2014, 128, 191-213.

14. Vainchtein, I.D.; Vinet, J.; Brouwer, N.; Brendecke, S.; Biagini, G.; Biber, K.; Boddeke, H.W.; Eggen, B.J. In acute experimental autoimmune encephalomyelitis, infiltrating macrophages are immune activated, whereas microglia remain immune suppressed. *Glia* 2014, 62, 1724-1735.

15. Nair, A.C.; Frederick, T.J.; Miller, S.D. Astrocytes in multiple sclerosis: A product of their environment. *Cellular and molecular life sciences : CMLS* 2008, 65, 2702-2720.

16. Hemmer, B.; Kerschensteiner, M.; Korn, T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. *The Lancet. Neurology* 2015, 14, 406-419.

17. Mahad, D.H.; Trapp, B.D.; Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. *The Lancet. Neurology* 2015, 14, 183-193.

18. Stitt, A.W.; Li, Y.M.; Gardiner, T.A.; Bucala, R.; Archer, D.B.; Vlassara, H. Advanced glycation end products (ages) co-localize with age receptors in the retinal vasculature of diabetic and of age-infused rats. *The American journal of pathology* 1997, 150, 523-531.

19. van Eupen, M.G.; Schram, M.T.; Colhoun, H.M.; Hanssen, N.M.; Niessen, H.W.; Tarnow, L.; Parving, H.H.; Rossing, P.; Stehouwer, C.D.; Schalkwijk, C.G. The methylglyoxal-derived age tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with ssvm-1. *Diabetologia* 2013, 56, 1845-1855.

20. Hanssen, N.M.; Wouters, K.; Huijbers, M.S.; Gijbels, M.J.; Sluimer, J.C.; Scheijen, J.L.; Heeneman, S.; Biessen, E.A.; Daemen, M.J.; Brownlee, M.; et al. Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. *European heart journal* 2014, 35, 1137-1146.

21. Gaens, K.H.J.; Goossens, G.H.; Niessen, P.M.; van Greevenbroek, M.M.; van der Kallen, C.J.H.; Niessen, H.W.; Rensen, S.S.; Buurman, W.A.; Greve, J.W.M.; Blaak, E.E., et al. N-epsilon-(carboxymethyl) lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. *Arterioscler Throm Vasc Biol* 2014, 34, 1199-1208.

22. Gaens, K.H.; Niessen, P.M.; Rensen, S.S.; Buurman, W.A.; Greve, J.W.; Diesseni, A.; Wolfs, M.G.; Hofker, M.H.; Bloemen, J.G.; Dejong, C.H., et al. Endogenous formation of neposlipid (carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. *J Hepatol* 2012, 56, 647-655.

23. Ahmed, N.; Ahmed, U.; Thornalley, P.J.; Hager, K.; Fleischer, G.; Munch, G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer’s disease and link to cognitive impairment. *Journal of neurochemistry* 2005, 92, 255-263.

24. Dallo, E.; Portero-Otin, M.; Ayala, V.; Martinez, A.; Pamplona, R.; Ferrer, I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. *Journal of neuropathology and experimental neurology* 2005, 64, 816-830.
25. Ledesma, M.D.; Bonay, P.; Avila, J. Tau protein from alzheimer’s disease patients is glycated at its tubulin-binding domain. *Journal of neurochemistry* 1995, 65, 1658-1664.

26. Vitek, M.P.; Bhattacharya, K.; Glendening, J.M.; Stopa, E.; Vlassara, H.; Bucala, R.; Manogue, K.; Cerami, A. Advanced glycation end products contribute to amyloidosis in alzheimer disease. *Proceedings of the National Academy of Sciences of the United States of America* 1994, 91, 4766-4770.

27. Sternberg, Z.; Hennies, C.; Sternberg, D.; Wang, P.; Kinkel, P.; Hojnacki, D.; Weinstock-Guttman, B.; Munschauer, F. Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis. *J Neuroinflammation* 2010, 7, 72.

28. Sternberg, Z.; Ostrow, P.; Vaughan, M.; Chichelli, T.; Munschauer, F. Age-rage in multiple sclerosis brain. *Immunological investigations* 2011, 40, 197-205.

29. Gaens, K.H.; Stehouwer, C.D.; Schallkijw, C.G. Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity. *Curr Opin Lipidol* 2013, 24, 4-11.

30. Singh, R.; Barden, A.; Mori, T.; Beilin, L. Advanced glycation end-products: A review. *Diabetologia* 2001, 44, 129-146.

31. Allaman, I.; Belanger, M.; Magistretti, P.J. Methylglyoxal, the dark side of glycolysis. *Frontiers in neuroscience* 2015, 9, 23.

32. Maessen, D.E.; Stehouwer, C.D.; Schallkijw, C.G. The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases. *Clinical science* 2015, 128, 839-861.

33. Lange, J.N.; Wood, K.D.; Knight, J.; Assimos, D.G.; Holmes, R.P. Glyoxal formation and its role in endogenous oxalate synthesis. *Advances in urology* 2012, 2012, 819202.

34. Pamplona, R. Advanced lipoxidation end-products. *Chemico-biological interactions* 2011, 192, 14-20.

35. Vistoli, G.; De Maddis, D.; Cipak, A.; Zarkovic, N.; Carini, M.; Aldini, G. Advanced glyoxidation and lipoxidation end products (ages and ales): An overview of their mechanisms of formation. *Free radical research* 2013, 47 Suppl 1, 3-27.

36. Matafome, P.; Sena, C.; Seica, R. Methylglyoxal, obesity, and diabetes. *Endocrine* 2013, 43, 472-484.

37. Di Loreto, S.; Caracciolo, V.; Colafarina, S.; Sebastiani, P.; Gasbarri, A.; Amicarelli, F. Methylglyoxal induces oxidative stress-dependent cell injury and up-regulation of interleukin-1beta and nerve growth factor in cultured hippocampal neuronal cells. *Brain research* 2004, 1006, 157-167.

38. Figarola, J.L.; Singhal, J.; Rahbar, S.; Awasthi, S.; Singhal, S.S. Lr-90 prevents methylglyoxal-induced oxidative stress and apoptosis in human endothelial cells. *Apoptosis : an international journal on programmed cell death* 2014, 19, 776-788.

39. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. *Nature* 2001, 414, 813-820.

40. Gaens, K.H.; Stehouwer, C.D.; Schallkijw, C.G. Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity. *Current opinion in lipidology* 2013, 24, 4-11.

41. Poulsen, M.W.; Hedegaard, R.V.; Andersen, J.M.; de Courtens, B.; Bugel, S.; Nielsen, J.; Skibsted, L.H.; Dragsted, L.O. Advanced glycation endproducts in food and their effects on health. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association* 2013, 60, 10-37.

42. Ott, C.; Jacobs, K.; Haucke, E.; Navarrete Santos, A.; Grune, T.; Simm, A. Role of advanced glycation end products in cellular signaling. *Redox biology* 2014, 2, 411-429.

43. Yan, S.F.; Ramasamy, R.; Schmidt, A.M. The rage axis: A fundamental mechanism signaling danger to the vulnerable vasculature. *Circulation research* 2010, 106, 842-853.

44. Dukic-Stefanovic, S.; Gasic-Milenkovic, J.; Deuther-Condard, W.; Munch, G. Signal transduction pathways in mouse microglia n-11 cells activated by advanced glycation endproducts (ages). *Journal of neurochemistry* 2003, 87, 44-55.

45. Wang, A.L.; Li, Z.; Yuan, M.; Yu, A.C.; Zhu, X.; Tso, M.O. Sinomenine inhibits activation of rat retinal microglia induced by advanced glycation end products. *International immunopharmacology* 2007, 7, 1552-1558.

46. Wang, L.; Chen, K.; Liu, K.; Zhou, Y.; Zhang, T.; Wang, B.; Mi, M. Dha inhibited ages-induced retinal microglia activation via suppression of the ppargamma/hkappab pathway and reduction of signal transducers in the ages/rage axis recruitment into lipid rafts. *Neurochemical research* 2015, 40, 713-722.

47. Shaikh, S.B.; Uy, B.; Perera, A.; Nicholson, I.F. Ages-rage mediated up-regulation of connexin43 in activated human microglial chme-5 cells. *Neurochemistry international* 2012, 60, 640-651.
494 48. Wang, Z.; Li, D.D.; Liang, Y.Y.; Wang, D.S.; Cai, N.S. Activation of astrocytes by advanced glycation end products: Cytokines induction and nitric oxide release. Acta pharmacologica Sinica 2002, 23, 974-980.
495 49. Begley, D.J.; Brightman, M.W. Structural and functional aspects of the blood-brain barrier. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 2003, 61, 39-78.
496 50. Hussain, M.; Bork, K.; Gnanapragassam, V.S.; Bennmann, D.; Jacobs, K.; Navarrete-Santos, A.; Hofmann, B.; Simm, A.; Danker, K.; Horstkorte, R. Novel insights in the dysfunction of human blood-brain barrier after glycation. Mechanisms of ageing and development 2016, 155, 48-54.
500 51. Shimizu, F.; Sano, Y.; Tominaga, O.; Maeda, T.; Abe, M.A.; Kanda, T. Advanced glycation end-products disrupt the blood-brain barrier by stimulating the release of transforming growth factor-beta by pericytes and vascular endothelial growth factor and matrix metalloproteinase-2 by endothelial cells in vitro. Neurobiology of aging 2013, 34, 1902-1912.
504 52. Miyajima, H.; Osanai, M.; Chiba, H.; Nishikiori, N.; Kojima, T.; Ohtsuka, K.; Sawada, N. Glyceraldehyde-derived advanced glycation end-products preferentially induce vegf expression and reduce gdnf expression in human astrocytes. Biochemical and biophysical research communications 2005, 330, 361-366.
507 53. Carvalho, A.N.; Lim, J.L.; Nijland, P.G.; Witte, M.E.; Van Horssen, J. Glutathione in multiple sclerosis: More than just an antioxidant? Mult Scler 2014, 20, 1425-1431.
511 54. Calabrese, V.; Scapagnini, G.; Ravagna, A.; Bella, R.; Foresti, R.; Bates, T.E.; Giuffrida Stella, A.M.; Pennisi, G. Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and s-nitrosothiols and with changes in glutathione levels. Journal of neuroscience research 2002, 70, 580-587.
514 55. Choi, I.Y.; Lee, S.P.; Denney, D.R.; Lynch, S.G. Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1h magnetic resonance chemical shift imaging at 3 t. Mult Scler 2011, 17, 289-296.
518 56. Srinivasan, R.; Ratiney, H.; Hammond-Rosenbluth, K.E.; Pelletier, D.; Nelson, S.J. Mr spectroscopic imaging of glutathione in the white and gray matter at 7 t with an application to multiple sclerosis. Magnetic resonance imaging 2010, 28, 163-170.
520 57. Junaid, M.A.; Kowal, D.; Barua, M.; Pullarkat, P.S.; Sklower Brooks, S.; Pullarkat, R.K. Proteomic studies identified a single nucleotide polymorphism in glyoxalase i as autism susceptibility factor. American journal of medical genetics. Part A 2004, 131, 11-17.
523 58. Sidoti, A.; Antognelli, C.; Rinaldi, C.; D'Angelo, R.; Dattola, V.; Girlanda, P.; Talesa, V.; Amato, A. Glyoxalase i a111e, paraoxonase 1 q192r and l55m polymorphisms: Susceptibility factors of multiple sclerosis? Mult Scler 2007, 13, 446-453.
527 59. Kelly, B.; O'Neill, L.A. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell research 2015, 25, 771-784.
532 60. Orihuela, R.; McPherson, C.A.; Harry, G.J. Microglial m1/m2 polarization and metabolic states. British journal of pharmacology 2015.
530 61. Bittner, C.X.; Loaiza, A.; Ruminot, I.; Larenas, V.; Sotelo-Hitschfeld, T.; Gutierrez, R.; Cordova, A.; Valdebenito, R.; Frommer, W.B.; Barros, L.F. High resolution measurement of the glycolytic rate. Frontiers in neuroenergetics 2010, 2.
534 62. Herrero-Mendez, A.; Almeida, A.; Fernandez, E.; Maestre, C.; Moncada, S.; Bolanos, J.P. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by apc/c-cdh1. Nature cell biology 2009, 11, 747-752.
536 63. Itoh, Y.; Esaki, T.; Shimoji, K.; Cook, M.; Law, M.J.; Kaufman, E.; Sokoloff, L. Dichloroacetate effects on glucose and lactate oxidation by neurons and astroglia in vitro and on glucose utilization by brain in vivo. Proceedings of the National Academy of Sciences of the United States of America 2003, 100, 4879-4884.
540 64. Karnovsky, M.L. Metabolic basis of phagocytic activity. Physiological reviews 1962, 42, 143-168.
541 65. Bogie, J.F.; Timmermans, S.; Huynh-Thu, V.A.; Irrthum, A.; Smeets, H.J.; Gustafsson, J.A.; Steffensen, K.R.; Mulder, M.; Stinissen, P.; Hellings, N., et al. Myelin-derived lipids modulate macrophage activity by liver x receptor activation. PLoS One 2012, 7, e44998.
544 66. Belanger, M.; Allaman, I.; Magistretti, P.J. Brain energy metabolism: Focus on astrocyte-neuron metabolic cooperation. Cell Metab 2011, 14, 724-738.
546 67. Nijland, P.G.; Michailidou, I.; Witte, M.E.; Mizee, M.R.; van der Pol, S.M.; van Het Hof, B.; Reijerkerk, A.; Pellerin, L.; van der Valk, P.; de Vries, H.E., et al. Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions. Glia 2014, 62, 1125-1141.
547 68. Jurcovicova, J. Glucose transport in brain - effect of inflammation. Endocrine regulations 2014, 48, 35-48.
548 69. Trapp, B.D.; Stys, P.K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. The Lancet. Neurology 2009, 8, 280-291.
549 70. Schiepers, C.; Van Hecke, P.; Vandenberghe, R.; Van Oostende, S.; Dupont, P.; Demaerel, P.; Bormans, G.; Carton, H. Positron emission tomography, magnetic resonance imaging and proton nmr spectroscopy of white matter in multiple sclerosis. Mult Scler 1997, 3, 8-17.
550 71. Schocke, M.F.; Berger, T.; Felber, S.R.; Wolf, C.; Deisenhammer, F.; Kremser, C.; Seppi, K.; Aichner, F.T. Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy. NeuroImage 2003, 20, 1253-1263.
551 72. Morland, C.; Henjum, S.; Iversen, E.G.; Skrede, K.K.; Hassel, B. Evidence for a higher glycolytic than oxidative metabolic activity in white matter of rat brain. Neurochemistry international 2007, 50, 703-709.
552 73. Funfschilling, U.; Supplie, L.M.; Mahad, D.; Boretius, S.; Saab, A.S.; Edgar, J.; Brinkmann, B.G.; Kassmann, C.M.; Tzvetanova, I.D.; Mobius, W., et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 2012, 485, 517-521.
553 74. van Horssen, J.; Witte, M.E.; Schreibelt, G.; de Vries, H.E. Radical changes in multiple sclerosis pathogenesis. Biochimica et biophysica acta 2011, 1812, 141-150.
554 75. Ljubisavljevic, S. Oxidative stress and neurobiology of demyelination. Molecular neurobiology 2014.
555 76. Mattsson, N.; Haghighi, S.; Andersen, O.; Yao, Y.; Rosengren, L.; Blennow, K.; Pratico, D.; Zetterberg, H. Elevated cerebrospinal fluid f2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Letters 2007, 214, 233-236.
556 77. van Horssen, J.; Schreibelt, G.; Dreuxhage, J.; Hazes, T.; Dijkstra, C.D.; van der Valk, P.; de Vries, H.E. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free radical biology & medicine 2008, 45, 1729-1737.
557 78. Wang, P.; Xie, K.; Wang, C.; Bi, J. Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis. European neurology 2014, 72, 249-254.
558 79. Andersson, A.; Covacu, R.; Sunnemark, D.; Danilov, A.I.; Dal Bianco, A.; Khademi, M.; Wallstrom, E.; Lobell, A.; Brundin, L.; Lassmann, H., et al. Pivotal advance: Hmg1 expression in active lesions of human and experimental multiple sclerosis. Journal of leukocyte biology 2008, 84, 1248-1255.
560 80. Yan, S.S.; Wu, Z.Y.; Zhang, H.P.; Furtado, G.; Chen, X.; Yan, S.F.; Schmidt, A.M.; Brown, C.; Stern, A.; LaFaille, J., et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic t-cell infiltration of the central nervous system. Nature medicine 2003, 9, 287-293.
561 81. Ding, Q.; Keller, J.N. Evaluation of rage isoforms, ligands, and signaling in the brain. Biochimica et biophysica acta 2005, 1746, 18-27.
562 82. Lillieniek, B.; Weigand, M.A.; Bierhaus, A.; Nicklas, W.; Kasper, M.; Hofer, S.; Plachky, J.; Grone, H.J.; Kurschus, F.C.; Schmidt, A.M., et al. Receptor for advanced glycation end products (rage) regulates sepsis but not the adaptive immune response. The journal of clinical investigation 2004, 113, 1641-1650.
563 83. Sternberg, Z.; Chiotti, A.; Tario, J.; Chichelli, T.; Patel, N.; Chadha, K.; Yu, J.; Karmon, Y. Reduced expression of membrane-bound (m)rage is a biomarker of multiple sclerosis disease progression. Immunobiology 2016, 221, 193-198.
564 84. Sternberg, Z.; Weinstock-Gutman, B.; Hojnacki, D.; Zamboni, P.; Zivadinov, R.; Chadha, K.; Lieberman, A.; Kazim, L.; Drake, A.; Rocca, P., et al. Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity. Mult Scler 2008, 14, 759-763.
565 85. Hofmann, M.A.; Drury, S.; Hudson, B.I.; Gleason, M.R.; Qu, W.; Lu, Y.; Lalla, E.; Chitnis, S.; Monteiro, J.; Stickland, M.H., et al. Rage and arthritis: The g82s polymorphism amplifies the inflammatory response. Genes and immunity 2002, 3, 123-135.
88. Hudson, B.I.; Stickland, M.H.; Futers, T.S.; Grant, P.J. Effects of novel polymorphisms in the rage gene on transcriptional regulation and their association with diabetic retinopathy. *Diabetes* 2001, 50, 1505-1511.

89. Tiszlavicz, Z.; Gyulai, Z.; Bencsik, K.; Szolnoki, Z.; Kocsis, A.K.; Somogyvari, F.; Vecsei, L.; Mandi, Y. Rage gene polymorphisms in patients with multiple sclerosis. *J Mol Neurosci* 2009, 39, 360-365.

90. Li, K.; Zhao, B.; Dai, D.; Yao, S.; Liang, W.; Yao, L.; Yang, Z. A functional p.82g>polymorphism in the rage gene is associated with multiple sclerosis in the chinese population. *Mult Scler* 2011, 17, 914-921.

91. Cai, W.; Ramdas, M.; Zhu, L.; Chen, X.; Striker, G.E.; Vlassara, H. Oral advanced glycation endproducts (ages) promote insulin resistance and diabetes by depleting the antioxidant defenses age receptor-1 and sirtuin 1. *Proceedings of the National Academy of Sciences of the United States of America* 2012, 109, 15888-15893.

92. Jiang, Z.; Jiang, J.X.; Zhang, G.X. Macrophages: A double-edged sword in experimental autoimmune encephalomyelitis. *Immunology letters* 2014, 160, 17-22.

93. Kotter, M.R.; Zhao, C.; van Rooijen, N.; Franklin, R.J. Macrophage-depletion induced impairment of experimental cns remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. *Neurobiology of disease* 2005, 18, 166-175.

© 2016 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).